



BLISS GVS PHARMA LIMITED

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2012

PART-I

(₹ in Lacs)

SR. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2012 (UNAUDITED)	31.03.2012 (UNAUDITED)	30.06.2011 (UNAUDITED)	31.03.2012 (AUDITED)
1	Income from Operations				
	(a) Net Sales (Net of Excise Duty)	6374.16	7071.52	5208.16	26442.53
	(b) Other Operating Income	59.66	67.92	16.72	224.96
	Total Income from Operations (Net)	6433.82	7139.44	5224.88	26667.49
2	Expenses				
	A) Consumption of Raw Materials	3517.49	4262.77	2473.99	14799.48
	B) Purchase of Traded Goods	60.17	217.62	-	1001.29
	C) (Increase)/Decrease in Stock in Trade	-209.42	-40.36	249.05	-53.60
	D) Employee Benefit Expenses	196.62	182.59	131.90	603.15
	E) Depreciation / Amortisation	106.74	65.53	155.00	364.61
	F) Other Expenditure	682.79	948.62	511.76	3198.95
	Total Expenses	4354.39	5636.77	3521.70	19913.88
3	Profit from operations before other Income & Finance Cost & Exceptional items (1-2)	2079.43	1502.68	1703.18	6753.61
4	Other Income	394.64	431.45	76.34	1620.05
5	Profit from ordinary Activities before Finance Cost (3+4)	2474.07	1934.13	1779.52	8373.66
6	Finance Cost	80.57	126.34	76.06	402.41
7	Profit from ordinary Activities after Finance Cost but before exceptional items (5-6)	2393.50	1807.79	1703.46	7971.25
8	Exceptional Items	-	-	-	-
9	Profit from ordinary Activities before Tax (7 - 8)	2393.50	1807.79	1703.46	7971.25
10	Tax Expense (Including Deferred Tax)	704.01	1041.11	344.95	2688.35
11	Net Profit after Tax for the period (9 - 10)	1689.49	766.68	1358.51	5282.90
12	Paid - Up Equity Capital	1031.47	1031.47	1031.47	1031.47
13	Reserves Excluding Revaluation Reserve (As Per Balance Sheet)	-	-	-	20011.63
14	Basic and Diluted EPS (Not Annualised)	1.64	0.74	1.32	5.12

PART-II

(₹ in Lacs)

SR. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2012 (UNAUDITED)	31.03.2012 (UNAUDITED)	30.06.2011 (UNAUDITED)	31.03.2012 (AUDITED)
A	PARTICULARS OF SHAREHOLDING				
1	Aggregate of Non-promoter Shareholding				
	- No. of Shares (Face Value Rs. 1/- each)	36187842	36187842	37206791	36187842
	- Percentage of Shareholding (%)	35.08	35.08	36.07	35.08
2	Promoter and Promoter group Shareholding				
	A) Pledge/ Encumbered				
	- No. of Shares (Face Value Re. 1/- each)	-	-	-	-
	- Percentage of Shares (As % of The Total Share Holding of Promoter & Promoter Group)	-	-	-	-
	- Percentage of Shares (As % of The Total Share Capital of The Company)	-	-	-	-
	B) Non - Encumbered				
	- No. of Shares (Face Value Re. 1/- each)	66958830	66958830	65939881	66958830
	- Percentage of Shares (As % of The Total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of The Total Share Capital of The Company)	64.92	64.92	63.93	64.92

SR. No.	PARTICULARS	QUARTER ENDED 30th June 2012
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	-
	Received during the quarter	3
	Disposed off during the quarter	3
	REMAINING UNSOLVED AT THE END OF THE QUARTER	-

Notes:

- The company operates primarily in the pharmaceutical business and hence has only one reportable segment.
- During the current Quarter, the company has Acquired 70% Stake in Kremoint Pharma Private Limited (KPPL) amounting to a total consideration of Rs. 18.03 Crores. Out of which consideration relating to 50% has been already paid and balance 20% is expected to be paid in near future. KPPL is engaged in Manufacturing of Pharmaceuticals and a leading company in the manufacture and export of creams, ointments and gels.
- The above results were reviewed by The Audit Committee & were there after approved By The Board at its meeting held on 10th August 2012.
- In view of the extant volatility in exchange rates and considering longer duration of exports receivables. Unrealised exchange gains aggregating to Rs. 416.95 Lakhs which would have been reported on Such exports receivables at the closing rate is not accounted for in the above interim financial statements. The same will be recognised in the books on actual settlement or at the year end which ever is earlier. The statutory auditors have brought this fact to the notice in their limited review report.

Place : Mumbai
Date : 10th August 2012

FOR BLISS GVS PHARMA LIMITED
SD/-
S. N. KAMATH
MANAGING DIRECTOR



Size: 28 cms (w) x 33 cms (h)

Head Office : Mumbai

- Tel : (022) 2200 0607 / 7318 / 6360
(022) 6631 5835 / 36
- Fax : (022) 2200 3476
- E-mail : info@bkkhareco.com
- 706 / 708, Sharda Chambers,
New Marine Lines, Mumbai 400 020

B. K. KHARE & Co.
CHARTERED ACCOUNTANTS

The Board of Directors
Bliss GVS Pharma Limited
Mumbai.

Dear Sirs,

Limited Review Report

We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **Bliss GVS Pharma Limited** for the period ended 30th June, 2011 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us.. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Other Committee. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with stock exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.

Branch Office : Pune

- Tel : (020) 64019743 / 25666932 / 32926341
- E-mail : pune@bkkhareco.com
- Hotel Swaroop, 4th Floor, Lane No.10,
Prabhat Road, Frandwane Pune - 411 004



Branch Office : Bengaluru


- Tel : (080) 4110 5357 •
- E-mail : bkkhareb@vsnl.net •
- 101, Money Chambers, 1st Floor •

#6K H Road, Shanthinagar, Bengaluru - 560027

Emphasis of Matter

We draw attention to Note No. 4 to the Statement regarding unrealised exchange gain of Rs. 416.95 lakhs relating to exports receivables not accounted for in view of extant volatility in exchange rates and longer duration of such receivables. Our conclusion is not modified in respect of this matter.

For B. K. Khare & Co.
Chartered Accountants
Firm Registration No. 105102W



Santosh Parab
... Partner
M.No.47942



Place: Mumbai
Date: 10th August 2012